Portico NG Approval Study

  • Research type

    Research Study

  • Full title

    Portico NG Approval Study - Evaluation of the Portico™ NG Transcatheter Aortic Valve in High and Extreme Risk Patients with Symptomatic Severe Aortic Stenosis

  • IRAS ID

    269254

  • Contact name

    Ganesh Manoharan

  • Contact email

    Ganesh.Manoharan@belfasttrust.hscni.net

  • Clinicaltrials.gov Identifier

    NCT04011722

  • Duration of Study in the UK

    2 years, 4 months, 28 days

  • Research summary

    The purpose of this research study is to collect data on the Portico NG TAVI system (Portico NG Transcatheter Aortic Valve, FlexNav delivery system and Portico NG Loading System), which is used to treat your heart valve disease, and to support commercial approval of the device.

    The Portico NG valve has been modified from its original (first-generation) design to include an outer cuff to reduce blood flow back to the heart and improve long term performance of the valve. The Portico NG valve is used in combination with the FlexNav delivery system, which has a smaller insertion size (compared to the first generation Portico delivery system), so it can more easily manoeuvre through narrow blood vessels, improve the doctor’s ability to precisely position the Portico NG valve in your diseased heart valve, and be easier for the study doctor to use.

    It is possible these design features may reduce some of the known risks associated with transcatheter aortic valve implantation (TAVI) procedures, specifically the risk of blood vessel injuries and bleeding or the need for additional treatment of the valve.

    The Study will enrol approximately 140 subjects at up to twenty sites in Europe, Australia and the USA. This will comprise of up to a total of 120 analysis subjects; in addition, up to a total of 20 roll-in subjects may be enrolled based on experience of the implanting physicians. Patient involvement will last approximately 12 months from the time of the implant procedure. At the end of the study, the patient will continue to be followed in accordance with local practice.

    The study will involve six visits:
    • Screening
    • Baseline
    • Implant
    • Discharge
    • 30-day follow-up
    • 12-month follow-up

  • REC name

    HSC REC B

  • REC reference

    19/NI/0161

  • Date of REC Opinion

    12 Sep 2019

  • REC opinion

    Favourable Opinion